Pinebridge Investments L.P. Purchases 6,507 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Pinebridge Investments L.P. lifted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 42.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 21,748 shares of the medical equipment provider's stock after acquiring an additional 6,507 shares during the quarter. Pinebridge Investments L.P.'s holdings in Lantheus were worth $1,946,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. increased its position in Lantheus by 47.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider's stock worth $1,041,000 after acquiring an additional 3,772 shares during the period. Empirical Asset Management LLC bought a new stake in Lantheus during the fourth quarter worth about $323,000. Focus Financial Network Inc. bought a new stake in shares of Lantheus during the 4th quarter worth approximately $292,000. Harbor Capital Advisors Inc. increased its stake in shares of Lantheus by 12.8% in the 4th quarter. Harbor Capital Advisors Inc. now owns 145,379 shares of the medical equipment provider's stock valued at $13,006,000 after purchasing an additional 16,466 shares during the last quarter. Finally, World Investment Advisors LLC acquired a new position in shares of Lantheus during the 3rd quarter worth $60,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Stock Up 1.5 %

LNTH traded up $1.58 during midday trading on Thursday, hitting $105.92. 979,689 shares of the company were exchanged, compared to its average volume of 951,309. The firm has a market capitalization of $7.25 billion, a P/E ratio of 17.62 and a beta of 0.20. The firm's 50 day moving average price is $98.78 and its 200-day moving average price is $95.20. Lantheus Holdings, Inc. has a 1-year low of $65.89 and a 1-year high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). The company had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, sell-side analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on LNTH shares. B. Riley dropped their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. JMP Securities reiterated a "market outperform" rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Finally, Truist Financial upped their target price on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Lantheus presently has a consensus rating of "Moderate Buy" and an average price target of $129.43.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 63,109 shares of company stock valued at $6,016,046 over the last quarter. Insiders own 1.50% of the company's stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.